{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"6100","upperLimit":"11500","value":"6230"},{"groupId":"OG001","lowerLimit":"11900","upperLimit":"16500","value":"13700"},{"groupId":"OG002","lowerLimit":"3570","upperLimit":"18700","value":"13900"},{"groupId":"OG003","lowerLimit":"21300","upperLimit":"44100","value":"32700"},{"groupId":"OG004","lowerLimit":"36700","upperLimit":"60900","value":"48500"},{"groupId":"OG006","lowerLimit":"11000","upperLimit":"42400","value":"26700"},{"groupId":"OG007","lowerLimit":"40100","upperLimit":"216000","value":"128000"},{"groupId":"OG008","lowerLimit":"38500","upperLimit":"56800","value":"47700"},{"groupId":"OG009","lowerLimit":"24100","upperLimit":"52800","value":"38500"},{"groupId":"OG010","lowerLimit":"10000","upperLimit":"28900","value":"18300"},{"groupId":"OG011","lowerLimit":"17100","upperLimit":"66100","value":"44700"},{"groupId":"OG012","lowerLimit":"35900","upperLimit":"83900","value":"64900"},{"groupId":"OG013","lowerLimit":"26300","upperLimit":"50200","value":"30100"},{"groupId":"OG014","lowerLimit":"22000","upperLimit":"37100","value":"32000"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"4"},{"groupId":"OG003","value":"2"},{"groupId":"OG004","value":"3"},{"groupId":"OG005","value":"0"},{"groupId":"OG006","value":"2"},{"groupId":"OG007","value":"2"},{"groupId":"OG008","value":"2"},{"groupId":"OG009","value":"2"},{"groupId":"OG010","value":"5"},{"groupId":"OG011","value":"5"},{"groupId":"OG012","value":"3"},{"groupId":"OG013","value":"3"},{"groupId":"OG014","value":"5"}],"units":"Participants"}],"title":"Cycle 1 day 1"},{"categories":[{"measurements":[{"groupId":"OG002","lowerLimit":"21100","upperLimit":"21100","value":"21100"},{"groupId":"OG003","lowerLimit":"3240","upperLimit":"3240","value":"3240"},{"groupId":"OG004","lowerLimit":"130000","upperLimit":"130000","value":"130000"},{"groupId":"OG006","lowerLimit":"20600","upperLimit":"84000","value":"52300"},{"groupId":"OG007","lowerLimit":"110000","upperLimit":"345000","value":"128000"},{"groupId":"OG008","lowerLimit":"111000","upperLimit":"191000","value":"118000"},{"groupId":"OG009","lowerLimit":"84600","upperLimit":"267000","value":"176000"},{"groupId":"OG010","lowerLimit":"31000","upperLimit":"74300","value":"52600"},{"groupId":"OG011","lowerLimit":"48700","upperLimit":"91300","value":"51800"},{"groupId":"OG013","lowerLimit":"0.00","upperLimit":"28300","value":"23600"},{"groupId":"OG014","lowerLimit":"33900","upperLimit":"133000","value":"86800"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"1"},{"groupId":"OG004","value":"1"},{"groupId":"OG005","value":"0"},{"groupId":"OG006","value":"2"},{"groupId":"OG007","value":"4"},{"groupId":"OG008","value":"3"},{"groupId":"OG009","value":"2"},{"groupId":"OG010","value":"2"},{"groupId":"OG011","value":"5"},{"groupId":"OG012","value":"0"},{"groupId":"OG013","value":"3"},{"groupId":"OG014","value":"6"}],"units":"Participants"}],"title":"Cycle 1 day 8"}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"4"},{"groupId":"OG003","value":"3"},{"groupId":"OG004","value":"3"},{"groupId":"OG005","value":"2"},{"groupId":"OG006","value":"3"},{"groupId":"OG007","value":"4"},{"groupId":"OG008","value":"3"},{"groupId":"OG009","value":"2"},{"groupId":"OG010","value":"5"},{"groupId":"OG011","value":"5"},{"groupId":"OG012","value":"3"},{"groupId":"OG013","value":"3"},{"groupId":"OG014","value":"6"}],"units":"Participants"}],"description":"Plasma concentrations of AMG 176 were determined using a validated assay. Noncompartmental analysis was performed for estimation of PK parameters. Concentrations below the LLOQ of 5.00 ng/mL were set to zero before data analysis.","dispersionType":"Full Range","groups":[{"description":"Participants with MM received AMG 176 Dose A BIW. AMG 176 was administered as an IV infusion in a 4-week cycle.","id":"OG000","title":"Part 1A Cohort 1 (MM): AMG 176 Dose A BIW"},{"description":"Participants with MM received AMG 176 Dose B IV BIW. AMG 176 was administered as an IV infusion in a 4-week cycle.","id":"OG001","title":"Part 1A Cohort 2 (MM): AMG 176 Dose B BIW"},{"description":"Participants with MM received AMG 176 Dose C BIW. AMG 176 was administered as an IV infusion in a 4-week cycle.","id":"OG002","title":"Part 1A Cohort 3 (MM): AMG 176 Dose C BIW"},{"description":"Participants with MM received AMG 176 Dose D BIW. AMG 176 was administered as an IV infusion in a 4-week cycle.","id":"OG003","title":"Part 1A Cohort 4 (MM): AMG 176 Dose D BIW"},{"description":"Participants with MM received AMG 176 Dose E BIW. AMG 176 was administered as an IV infusion in a 4-week cycle.","id":"OG004","title":"Part 1A Cohort 5 (MM): AMG 176 Dose E BIW"},{"description":"Participants with MM received AMG 176 Dose G BIW. AMG 176 was administered as an IV infusion in a 4-week cycle.","id":"OG005","title":"Part 1A Cohort 6 (MM): AMG 176 Dose G BIW"},{"description":"Participants with MM received AMG 176 Dose E in cycle 1 week 1, then received Dose F BIW. AMG 176 was administered as an IV infusion in a 4-week cycle.","id":"OG006","title":"Part 1A Cohort 7 (MM): AMG 176 Dose E Then Dose F BIW"},{"description":"Participants with MM received AMG 176 Dose E in cycle 1 week 1, then received Dose G BIW. AMG 176 was administered as an IV infusion in a 4-week cycle.","id":"OG007","title":"Part 1A Cohort 8 (MM): AMG 176 Dose E Then Dose G BIW"},{"description":"Participants with MM received AMG 176 Dose E in cycle 1 week 1, then received Dose H BIW. AMG 176 was administered as an IV infusion in a 4-week cycle.","id":"OG008","title":"Part 1A Cohort 9 (MM): AMG 176 Dose E Then Dose H BIW"},{"description":"Participants with MM received AMG 176 Dose E in cycle 1 week 1, then received Dose I BIW. AMG 176 was administered as an IV infusion in a 4-week cycle.","id":"OG009","title":"Part 1A Cohort 10 (MM): AMG 176 Dose E Then Dose I BIW"},{"description":"Participants with AML received AMG 176 Dose D BIW. AMG 176 was administered as an IV infusion in a 4-week cycle.","id":"OG010","title":"Part 3 Cohort 1 (AML): AMG 176 Dose D BIW"},{"description":"Participants with AML received AMG 176 Dose E BIW. AMG 176 was administered as an IV infusion in a 4-week cycle.","id":"OG011","title":"Part 3 Cohort 2 (AML): AMG 176 Dose E BIW"},{"description":"Participants with AML received AMG 176 Dose E in cycle 1 week 1, then received Dose F BIW. AMG 176 was administered as an IV infusion in a 4-week cycle.","id":"OG012","title":"Part 3 Cohort 3 (AML): AMG 176 Dose E Then Dose F BIW"},{"description":"Participants with AML received AMG 176 Dose E BIW. AMG 176 was administered as an IV infusion in a 4-week cycle. They also received 75 mg/m\\^2 azacitidine SC or IV QD for 7 days in week 1.","id":"OG013","title":"Part 4 Cohort 5A (AML): AMG 176 Dose E BIW + Azacitidine"},{"description":"Participants with AML received AMG 176 Dose E in cycle 1 week 1, then received Dose G BIW. AMG 176 was administered as an IV infusion in a 4-week cycle. They also received 75 mg/m\\^2 azacitidine SC or IV QD for 7 days in week 1.","id":"OG014","title":"Part 4 Cohort 5B (AML): AMG 176 Dose E the Dose G BIW + Azacitidine"}],"paramType":"MEDIAN","populationDescription":"The PK analysis set included all participants who had received at least 1 dose of AMG 176 and had at least 1 PK sample collected. AUC0-24 was pre-specified in Parts 1A, 3A (Cohorts 1, 2, and 3) and 4 (Cohorts 5A and 5B) and participants with data available at each time point are presented.","reportingStatus":"POSTED","timeFrame":"Parts 1A, 3A and, 4: Cycle 1 day 1 pre, EOI, 1, 2, 3, 5, and 7 hrs EOI, cycle 1 day 8 pre and EOI","title":"Area Under the Concentration-time Curve (AUC) From Time 0 to 24 Hours (AUC0-24) of AMG 176 (Parts 1A, 3A [Cohorts 1, 2, and 3], and 4 [Cohorts 5A and 5B])","type":"PRIMARY","unitOfMeasure":"hour*ng/mL"}